Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 10/20 | 0.82 |
| ▸ | FER | P16591 | 9/20 | 0.82 |
| ▸ | JAK2 | O60674 | 2/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.64 |
| ▸ | HCK | P08631 | 2/20 | 0.64 |
| ▸ | ROS1 | P08922 | 2/20 | 0.64 |
| ▸ | PIM1 | P11309 | 2/20 | 0.64 |
| ▸ | PRKACA | P17612 | 2/20 | 0.64 |
| ▸ | MARK3 | P27448 | 2/20 | 0.64 |
| ▸ | LTK | P29376 | 2/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.64 |
| ▸ | CLK2 | P49760 | 2/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.64 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.64 |
| ▸ | MAP3K10 | Q02779 | 2/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.64 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.64 |
| ▸ | STK3 | Q13188 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2716733 | 1.00 | SYK (0.82) | SYKFERJAK2ROCK2MAP4K4 | |
| SCHEMBL2713511 | 0.90 | SYK (1.00) | SYKFERJAK2ROCK2MAP4K4 | |
| SCHEMBL2713216 | 0.90 | SYK (1.00) | SYKFERJAK2ROCK2MAP4K4 | |
| SCHEMBL16164019 | 0.84 | FER (0.66) | SYKFERMAPK1KCNH2MAPK3 | |
| SCHEMBL6154803 | 0.81 | SYK (0.85) | SYKFERJAK2ROCK2MAP4K4 | |
| SCHEMBL6154806 | 0.81 | SYK (0.85) | SYKFERJAK2ROCK2MAP4K4 | |
| SCHEMBL10250587 | 0.80 | FER (0.82) | SYKFERJAK2ROCK2MAP4K4 | |
| SCHEMBL19901818 | 0.80 | FER (0.78) | SYKFERJAK2ROCK2MAP4K4 | |
| SCHEMBL18925786 | 0.79 | SYK (0.77) | SYKFERJAK2ROCK2MAP4K4 | |
| SCHEMBL9233108 | 0.79 | SYK (0.77) | SYKFERJAK2ROCK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902688-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9359375-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8846928-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | SYK 1/4885FER 77/4885JAK2 29/4885 |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | SYK 1/4885FER 77/4885JAK2 29/4885 |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | SYK 1/4885FER 77/4885JAK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.